FDA Defends Approval of Controversial Alzheimer’s Drug
MONDAY, June 7, 2021 (HealthDay News) — The U.S. Food and Drug Administration has approved the first new drug to treat Alzheimer’s disease in nearly two decades, in a controversial decision that left the agency defending its reputation and its science. Aduhelm (aducanumab) treats Alzheimer’s by clearing out amyloid beta,Continue Reading